Sprint Bioscience AB (SPRINT.ST)
Sprint Bioscience AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Huddinge, AB, SE. The stock last traded at $3.05, up 9.71% on the session, giving a market capitalisation of $321.8M. Its beta of -0.52 implies it has historically moved less than the broad market.
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Sprint Bioscience AB is most often compared with the following Healthcare names: